|
 In one study, the treatment, mepolizumab, showed
statistically significant reduction in the frequency of
exacerbations in patients of severe eosinophilic asthma compared
with a placebo, GSK said on Wednesday.
The second study showed that patients on mepolizumab achieved
greater reduction in their oral corticosteroid dose compared with
those on placebo, while maintaining asthma control.
The company said the drug was administered to patients intravenously
or through subcutaneous injections every four weeks in the first
study.
In the second trial, the drug was administered through subcutaneous
injections.
The company said it would file for regulatory approval for the drug
globally by the end of the year.
GSK's shares closed 1.5 percent lower at 1670.5 pence on Wednesday
on the London Stock Exchange. (Reporting by Tasim Zahid in
Bangalore; editing by Kirti Pandey)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
